[Edaily NA EUN-KYUNG Reporter] Drug delivery platform company Inventage Lab Inc.(389470)has filed an international patent (PCT) application for its “IVL-BioFluidic” subcutaneous (SC) injection platform for ultra-high-concentration antibody drugs. Following the signing of six material transfer agreements (MTAs) since the platform’s unveiling last year, the company plans to expand discussions on joint development and technology transfer with global pharmaceutical companies by securing the patent and establishing a mass production system.

Inventage Lab Inc. announced on the 29th that it has completed the PCT international patent application for the IVL-BioFluidic technology and will present key research findings in an oral presentation at “PODD 2026 (Partnership Opportunities in Drug Delivery),” a drug delivery conference taking place in Boston, USA, on October 29–30.

IVL-Biofluidic is a platform that formulates antibodies at ultra-high concentrations to enable subcutaneous injection of high-dose antibody drugs. Unlike conventional methods that create high-concentration antibodies in liquid form, this platform converts antibodies into microparticles and suspends them in a low-viscosity solution.

Generally, as the concentration of liquid antibodies increases, viscosity rises, requiring more force to push the solution through a syringe and potentially making administration via a fine needle more difficult. IVL-Biofluidic aims to reduce the burden of administration caused by increased viscosity at high concentrations by converting antibodies into particles.

Competition to secure technologies for converting high-dose biologics to subcutaneous injection is also intensifying. Halozyme, a leading company in subcutaneous formulation conversion technology, acquired Elektrofi—which owns the “Hypercon” ultra-high-concentration microparticle technology—in early November of last year. According to documents filed by Halozime with the U.S. Securities and Exchange Commission (SEC), the final acquisition price was approximately $810.4 million (about 1.1 trillion won). Hypercon is a technology that converts biopharmaceuticals into microparticles, enabling the administration of the same dose of medication in a smaller volume.

In December of the same year, Halozime also acquired Surf Bio, a company developing high-concentration biopharmaceutical delivery technology. Halozime is expanding its drug delivery platform by integrating these high-concentration formulation technologies into its existing hyaluronidase-based “ENHANZE” product. In the company’s 2025 annual earnings report, the acquisitions of Electropie and Surf Bio were also described as part of a strategy to expand its drug delivery technology portfolio.

Inventage Lab Inc. is also proceeding with the patenting process for IVL-Biofluidic. The company has been conducting patent and freedom-to-operate (FTO) analyses related to ultra-high-concentration antibody particle technology since 2024 and plans to secure patent rights in individual countries, starting with this PCT application.

The PCT is a system that allows companies to file for patents in multiple countries through a single international application. Filing a PCT application does not in itself mean that patent rights have been obtained in each country; the company must select the countries it intends to enter and undergo the examination process in each country.

Inventage Lab Inc. official stated, “We have been preparing in terms of technology and intellectual property rights since 2024 by conducting patent and freedom-to-operate (FTO) analyses for our ultra-high-concentration antibody drug particulation technology,” adding, “As we have been receiving continuous inquiries about the technology and requests for additional data from global pharmaceutical companies since the platform’s unveiling, we will utilize this PCT application as a process to secure rights for global joint development and commercialization.”

External validation of IVL-Biofluidic is also expanding. Since first unveiling the platform at PODD last year, Inventage Lab Inc. has signed a total of six Material Transfer Agreements (MTAs) with global pharmaceutical companies and biotech ventures to date and is conducting joint research.

An MTA is a stage in which a partner company provides materials, such as antibodies, to Inventage Lab Inc., which then applies them to the IVL-Biofluidic platform to verify formulation feasibility and physical properties. While it does not guarantee a technology transfer agreement, it serves as a preliminary step toward subsequent joint development or technology transfer discussions, as it allows the platform’s performance to be validated using the actual drug candidates of potential partners.

The company explained that it has achieved the goal of ultra-high-concentration particle formation set at the time of the platform’s unveiling and is currently developing formulations with even higher concentrations. It is conducting related research with partner companies to expand the platform’s applicability to include antibody drugs that require high-dose administration.

The company will present the relevant research results at PODD 2026, which will be held next month. Inventage Lab Inc. will deliver a presentation titled “IVL-Biofluidic: Realizing Ultra-High-Concentration Biopharmaceutical Formulations through Microfluidics” on October 29, the first day of the conference.

According to the official schedule released by PODD, Inventage Lab Inc.’s presentation will take place starting at 1:30 p.m. on the 29th. The presentation is expected to cover the principles behind ultra-high-concentration biopharmaceutical formulations based on microparticle suspensions, approaches to addressing challenges in the administration of high-dose biopharmaceuticals, and experimental results obtained to date.

Presentations by global companies on subcutaneous injection technology for high-concentration biopharmaceuticals are also scheduled for this conference. Halozyme will present on “Advances in Formulations of High-Concentration, High-Dose Protein Therapeutics for Subcutaneous Administration,” and Nanoform will also participate in the session on injectable formulation technology. Representatives from global pharmaceutical companies such as Roche, Pfizer, Johnson & Johnson (J&J), Gilead, and Novartis will also attend as speakers and session chairs.

Inventage Lab Inc. plans to hold partnering meetings with multiple companies, including global pharmaceutical firms, during PODD. The company plans to discuss the potential for follow-up joint development and technology transfer based on data secured through existing Material Transfer Agreements (MTAs).

Inventage Lab Inc. is also concurrently establishing a production system for commercialization. Inventage Lab Inc. plans to apply the experience gained from developing its own production equipment and establishing a Good Manufacturing Practice (GMP) production system during the development of its existing long-acting injectable platform, “IVL-DrugFluidic,” and its gene therapy delivery platform, “IVL-GeneFluidic”(IVL-GeneFluidic), and plans to apply that experience to IVL-BioFluidic.

The company is currently finalizing plans for manufacturing facilities and mass production systems dedicated to IVL-BioFluidic. According to the company, ensuring that the particle size and formulation characteristics achieved in the laboratory remain consistent even when production scale is expanded is a key challenge for future technology transfer and commercial production.

An Inventage Lab Inc. official stated, “We are currently reviewing the feasibility of applying antibody drugs at higher concentrations with our partner companies and are finalizing plans for manufacturing facilities and mass production systems,” adding, “With this PCT application and the PODD announcement, we will expand our collaboration with global partners into follow-up joint development and technology transfer discussions.”